MCID: RBS001
MIFTS: 62

Rabies

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Rabies

MalaCards integrated aliases for Rabies:

Name: Rabies 12 76 53 59 55 43 3 44 15 73
Lyssa 12 53

Characteristics:

Orphanet epidemiological data:

59
rabies
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Rabies

MedlinePlus : 43 Rabies is a deadly animal disease caused by a virus. It can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. People get it from the bite of an infected animal. In people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. Once the symptoms begin, the disease is usually fatal. A series of shots can prevent rabies in people exposed to the virus. You need to get them right away. If an animal bites you, wash the wound well; then get medical care. To help prevent rabies Vaccinate your pet. Rabies vaccines are available for dogs, cats and farm animals Don't let pets roam Don't approach stray animals. Animals with rabies might be aggressive and vicious, or tired and weak Centers for Disease Control and Prevention

MalaCards based summary : Rabies, also known as lyssa, is related to encephalitis and polyradiculoneuropathy, and has symptoms including fever, headache and prickling or itching sensation at the site of bite. An important gene associated with Rabies is PML (Promyelocytic Leukemia), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Atovaquone and chloroquine have been mentioned in the context of this disorder. Affiliated tissues include brain or, brain and testes, and related phenotypes are depressivity and hallucinations

CDC : 3 Get Email Updates

Disease Ontology : 12 A viral infectious disease that results in inflammation located in brain or located in spinal cord, has material basis in Rabies virus, which is transmitted by bite of an infected animal, or transmitted by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.

Wikipedia : 76 Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early... more...

Related Diseases for Rabies

Diseases related to Rabies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 encephalitis 29.2 CCL5 CXCL10 IRF3 TLR3
2 polyradiculoneuropathy 29.1 ALB CCL5 STAT1
3 viral encephalitis 29.0 CCL5 CXCL10 MX1
4 meningoencephalitis 28.8 ALB CCL5 CD40LG
5 japanese encephalitis 28.5 CCL5 CXCL10 STAT1 TLR3
6 acute hemorrhagic leukoencephalitis 11.0
7 axillary adenitis 10.6 CD40LG STAT1
8 zika fever 10.6 CD40LG STAT1
9 colorado tick fever 10.6 ALB CD40LG
10 cork-handlers' disease 10.6 ALB CD40LG
11 coccidioidomycosis 10.5 CD40LG STAT1
12 plasmodium malariae malaria 10.5 ALB CD40LG
13 fournier gangrene 10.5 ALB CD40LG
14 parasitic ichthyosporea infectious disease 10.5 CD40LG NCAM1
15 intestinal perforation 10.5 NCAM1 NFKB1
16 rhinosporidiosis 10.4 CD40LG NCAM1
17 microphthalmia with limb anomalies 10.4 MX1 STAT1 STAT2
18 encephalitozoonosis 10.4 CD40LG MX1
19 mumps 10.3 CD40LG STAT1 STAT2
20 yellow nail syndrome 10.3 ALB CD40LG
21 mouth disease 10.3 IRF3 MX1 STAT1
22 west nile virus 10.3 IRF3 MX1 TLR3
23 neuronitis 10.3
24 hepatitis e 10.3 ALB CD40LG TLR3
25 aleutian mink disease 10.2 ALB CD40LG NGFR
26 measles 10.2 CD40LG STAT1 TLR3
27 japanese spotted fever 10.2 CD40LG CXCL10
28 acrodermatitis 10.1 ALB CXCL10
29 tick-borne encephalitis 10.1 ALB CXCL10 TLR3
30 diffuse glomerulonephritis 10.1 ALB CD40LG
31 rift valley fever 10.1 CD40LG MX1
32 viral hepatitis 10.1 ALB CD40LG MX1
33 vaccinia 10.0
34 dengue hemorrhagic fever 10.0 ALB CD40LG STAT1 STAT2
35 aging 10.0
36 splenic disease 10.0 ALB CD40LG
37 asymptomatic neurosyphilis 10.0 CD40LG CXCL10
38 primary bacterial infectious disease 9.9 ALB CD40LG CXCL10
39 human t-cell leukemia virus type 2 9.9 NFKB1 STAT1
40 tetanus 9.9
41 transmitted_by 9.9
42 type i 9.9
43 hepatitis c 9.9 CXCL10 IRF3 STAT1 TLR3
44 african tick-bite fever 9.8 CCL5 CD40LG
45 neuroblastoma 9.8
46 malaria 9.8
47 erythema multiforme 9.8
48 eastern equine encephalitis 9.8
49 st. louis encephalitis 9.8
50 psychotic disorder 9.8

Graphical network of the top 20 diseases related to Rabies:



Diseases related to Rabies

Symptoms & Phenotypes for Rabies

Symptoms:

12
  • fever
  • headache
  • prickling or itching sensation at the site of bite
  • anxiety
  • confusion
  • agitation
  • delirium
  • difficulty swallowing
  • hydrophobia
  • paralysis

Human phenotypes related to Rabies:

59 32 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 depressivity 59 32 hallmark (90%) Very frequent (99-80%) HP:0000716
2 hallucinations 59 32 hallmark (90%) Very frequent (99-80%) HP:0000738
3 anxiety 59 32 hallmark (90%) Very frequent (99-80%) HP:0000739
4 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
5 sudden cardiac death 59 32 occasional (7.5%) Occasional (29-5%) HP:0001645
6 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
7 diarrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002014
8 nausea and vomiting 59 32 hallmark (90%) Very frequent (99-80%) HP:0002017
9 anorexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002039
10 migraine 59 32 hallmark (90%) Very frequent (99-80%) HP:0002076
11 paresthesia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003401
12 excessive salivation 59 32 hallmark (90%) Very frequent (99-80%) HP:0003781
13 reduced consciousness/confusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0004372
14 attention deficit hyperactivity disorder 59 32 hallmark (90%) Very frequent (99-80%) HP:0007018
15 cerebral palsy 59 32 frequent (33%) Frequent (79-30%) HP:0100021
16 recurrent pharyngitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100776
17 insomnia 59 32 hallmark (90%) Very frequent (99-80%) HP:0100785
18 vocal cord paresis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001604
19 behavioral abnormality 59 Very frequent (99-80%)

UMLS symptoms related to Rabies:


fever, pruritus

MGI Mouse Phenotypes related to Rabies:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 IKBKE IRF3 MAP3K8 NCAM1 NFKB1 NGFR
2 hematopoietic system MP:0005397 9.85 TLR3 MAP3K8 NFKB1 NGFR CCL5 PML
3 immune system MP:0005387 9.73 IRF3 MAP3K8 NFKB1 NGFR PML CCL5
4 mortality/aging MP:0010768 9.36 TLR3 MAP3K8 NCAM1 NFKB1 NGFR ALB

Drugs & Therapeutics for Rabies

Drugs for Rabies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atovaquone Approved Phase 4 95233-18-4 74989
2
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
3
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
4
Proguanil Approved Phase 4 500-92-5 4923
5 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Antibodies, Blocking Phase 4,Phase 2,Not Applicable
9 Anti-Bacterial Agents Phase 4,Phase 1
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antimetabolites Phase 4,Phase 2,Not Applicable
12 Antirheumatic Agents Phase 4,Phase 2
13 Analgesics Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Anthelmintics Phase 4
16 Anti-Inflammatory Agents Phase 4
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4
18 Antimalarials Phase 4,Phase 3
19 Antiparasitic Agents Phase 4,Phase 3
20 Antiprotozoal Agents Phase 4,Phase 3
21 Atovaquone, proguanil drug combination Phase 4
22 Chloroquine diphosphate Phase 4 50-63-5
23 Peripheral Nervous System Agents Phase 4
24
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
25
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
26
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
27
Lactitol Investigational Phase 3 585-86-4 3871
28 gamma-Globulins Phase 2, Phase 3,Phase 1,Not Applicable
29 Immunoglobulins, Intravenous Phase 2, Phase 3,Phase 1,Not Applicable
30 Rho(D) Immune Globulin Phase 2, Phase 3,Phase 1,Not Applicable
31 Cathartics Phase 3
32 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
33 Laxatives Phase 3
34 Complement C3 Phase 3
35 Renal Agents Phase 3
36
Aluminum hydroxide Approved, Investigational Phase 2,Phase 1 21645-51-2
37
Abacavir Approved, Investigational Phase 2 136470-78-5 65140 441300
38
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
39
Lamivudine Approved, Investigational Phase 2,Not Applicable 134678-17-4 60825
40
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
41
Zidovudine Approved Phase 2 30516-87-1 35370
42 Antibodies, Monoclonal Phase 2
43
QS 21 Phase 2,Phase 1 141256-04-4
44 Adjuvants, Immunologic Phase 2,Phase 1,Not Applicable
45 Antacids Phase 2,Phase 1
46 Anti-Ulcer Agents Phase 2,Phase 1
47 Antifungal Agents Phase 2
48 Anti-HIV Agents Phase 2,Not Applicable
49 Anti-Retroviral Agents Phase 2,Not Applicable
50 Antiviral Agents Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
2 Diagnostic Immunization With Rabies Vaccine in Patients With PID Unknown status NCT02490956 Phase 4
3 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
4 Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules Completed NCT01365494 Phase 4
5 Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG Completed NCT01137045 Phase 4
6 Immunogenicity of Rabies Vaccine for Pre Exposure Completed NCT02374814 Phase 4 Rabies vaccine;Placebo
7 A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children Completed NCT02991872 Phase 4
8 Immunogenicity and Safety of Verorab™ in Indian Population Completed NCT00260351 Phase 4
9 The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use Completed NCT01821911 Phase 4
10 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Recruiting NCT02564471 Phase 4 Chloroquine;Atovaquone and Proguanil;Doxycycline
11 Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics Not yet recruiting NCT03557008 Phase 4 Metronidazole;Vancomycin;Neomycin Sulfate
12 A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children Withdrawn NCT03192371 Phase 4
13 Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects Unknown status NCT02040090 Phase 2, Phase 3 Active rabies vaccine (US-FDA approved)
14 Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age Completed NCT02177032 Phase 3
15 Simplifying the Rabies Pre-exposure Vaccination Completed NCT01388985 Phase 3
16 Early Rabies Vaccine Immunization in Primary School Children Completed NCT01107275 Phase 3
17 A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Completed NCT02491541 Phase 3
18 Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine Completed NCT01339312 Phase 3
19 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Completed NCT01662440 Phase 3
20 A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults Completed NCT01680016 Phase 3
21 Purified Rabies Vaccine for Human Use (Chick-embryo Cell) Completed NCT00345319 Phase 3
22 Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) Completed NCT00825305 Phase 3
23 Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans Completed NCT02288286 Phase 3
24 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
25 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
26 Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa Completed NCT00866619 Phase 3
27 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Recruiting NCT02912845 Phase 3 KamRAB - HRIG
28 A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. Active, not recruiting NCT02545517 Phase 3
29 Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects Active, not recruiting NCT03264157 Phase 2, Phase 3 HRIG
30 Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen Active, not recruiting NCT01622062 Phase 3
31 Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Active, not recruiting NCT03143218 Phase 3 SMC with SP+AQ;SMC placebo
32 One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding Unknown status NCT02276625 Phase 2
33 Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine Unknown status NCT00652275 Phase 2
34 Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Completed NCT02956421 Phase 2
35 Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen Completed NCT01930357 Phase 2
36 Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen Completed NCT01877395 Phase 2
37 A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines Completed NCT02956746 Phase 1, Phase 2
38 Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use Completed NCT01784874 Phase 2
39 Immunogenicity and Safety of a Purified Vero Rabies Vaccine Completed NCT03145766 Phase 2
40 Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults Completed NCT01228383 Phase 2
41 Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults Completed NCT00948272 Phase 2
42 Rabies Immunization Concomitant With JEV in Children Completed NCT00703521 Phase 2
43 Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents Completed NCT00708084 Phase 2
44 A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Completed NCT00656097 Phase 2
45 Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Completed NCT02559921 Phase 2
46 Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Completed NCT00694460 Phase 2
47 Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali Completed NCT00460525 Phase 2
48 Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine Completed NCT00223990 Phase 2
49 Efficacy of Malaria Vaccines in Kenyan Adults Completed NCT01666925 Phase 2
50 Efficacy of Candidate Malaria Vaccines in Senegalese Adults Completed NCT01658696 Phase 2

Search NIH Clinical Center for Rabies

Cochrane evidence based reviews: rabies

Genetic Tests for Rabies

Anatomical Context for Rabies

The Foundational Model of Anatomy Ontology organs/tissues related to Rabies:

19
Brain Or

MalaCards organs/tissues related to Rabies:

41
Brain, Testes, Spinal Cord, Bone Marrow, Liver, Bone, Skin

Publications for Rabies

Articles related to Rabies:

(show top 50) (show all 826)
# Title Authors Year
1
Notes from the Field: Assessment of Rabies Exposure Risk Among Residents of a University Sorority House - Indiana, February 2017. ( 29420465 )
2018
2
Qualitative Evaluation of the Five-Year 'Red Collar' Campaign to End Inhumane Culling of Dogs as a Method of Rabies Control. ( 29415427 )
2018
3
Evolutionary analysis of rabies virus isolates from Guangxi Province of southern China. ( 29914504 )
2018
4
Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine. ( 29416659 )
2018
5
Development of a genotype-by-sequencing immunogenetic assay as exemplified by screening for variation in red fox with and without endemic rabies exposure. ( 29321894 )
2018
6
Immunogenic response in obese patients undergoing rabies post-exposure prophylaxis with combined equine rabies immunoglobulin and rabies vaccination. ( 29191737 )
2018
7
Pre-exposure intradermal rabies vaccination: a non-inferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days. ( 29939243 )
2018
8
Genome Sequence of a Rabies Virus Isolated from a Dog in Chiapas, Mexico, 2013. ( 29371371 )
2018
9
An assessment of shedding with the oral rabies virus vaccine strain SPBN GASGAS in target and non-target species. ( 29325820 )
2018
10
Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: a systematic literature review and meta-analysis. ( 29939085 )
2018
11
Cerebrospinal fluid changes in cattle with rabies or with BoHV-5 meningoencephalitis and its correlation with the severity of CNS inflammatory process. ( 29684815 )
2018
12
The early use of Pasteur's rabies vaccine in the United States. ( 29921493 )
2018
13
Development of a relative potency test using ELISA for human rabies vaccines. ( 29970288 )
2018
14
Replication-incompetent rabies virus vector harboring glycoprotein gene of lymphocytic choriomeningitis virus (LCMV) protects mice from LCMV challenge. ( 29659579 )
2018
15
Barriers of attendance to dog rabies static point vaccination clinics in Blantyre, Malawi. ( 29324737 )
2018
16
Defining objective clusters for rabies virus sequences using affinity propagation clustering. ( 29357361 )
2018
17
Quality of horse F(ab')<sub>2</sub> antitoxins and anti-rabies immunoglobulins: protein content and anticomplementary activity. ( 29946337 )
2018
18
A retrospective evaluation of bites at risk of rabies transmission across 7 years: The need to improve surveillance and reporting systems for rabies elimination. ( 29965994 )
2018
19
In Honor of Dr. Ahmad Fayaz, A Prominent Rabies Researcher. ( 29940746 )
2018
20
First case of Stevens-Johnson syndrome after rabies vaccination. ( 29333656 )
2018
21
In-depth genome analyses of viruses from vaccine-derived rabies cases and corresponding live-attenuated oral rabies vaccines. ( 29439868 )
2018
22
Additional Progress in the Development and Application of a Direct, Rapid Immunohistochemical Test for Rabies Diagnosis. ( 29925781 )
2018
23
Evaluation of G2 Citric Acid-Based Dendrimer as an Adjuvant in Veterinary Rabies Vaccine. ( 29328884 )
2018
24
Human Exposure to Ferret Badger Rabies in Taiwan. ( 29954098 )
2018
25
A milestone towards eliminating rabies. ( 29954998 )
2018
26
Introduction and Establishment of Raccoon Rabies on Islands: Jekyll Island, Georgia as a Case Study. ( 29369728 )
2018
27
Characterization of rabies post-exposure prophylaxis in a region of the eastern Amazon, state of ParA!, Brazil, between 2000 and 2014. ( 29424092 )
2018
28
The influence of poverty and rabies knowledge on healthcare seeking behaviors and dog ownership, Cameroon. ( 29927935 )
2018
29
Knowledge of rabies and dog-related behaviors among people in Siem Reap Province, Cambodia. ( 29930480 )
2018
30
Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses. ( 29300155 )
2018
31
Geography but not alternative host species explain the spread of raccoon rabies virus in Vermont. ( 29941066 )
2018
32
New global strategic plan to eliminate dog-mediated rabies by 2030. ( 29929890 )
2018
33
Practical inter-sectoral linking: Tool to rabies One Health coordination to the grass-roots level. ( 29978578 )
2018
34
Potential Confounding of Diagnosis of Rabies in Patients with Recent Receipt of Intravenous Immune Globulin. ( 29420464 )
2018
35
Immunological Effect of aGV Rabies Vaccine Administered Using the Essen and Zagreb Regimens: A Double-Blind, Randomized Clinical Trial. ( 29394147 )
2018
36
MALT1 controls attenuated rabies virus by inducing early inflammation and T cell activation in the brain. ( 29367251 )
2018
37
Production of Recombinant Rabies Virus Glycoprotein by Insect Cells in a Single-Use Fixed-Bed Bioreactor. ( 28921430 )
2018
38
First confirmed case of human rabies in Saudi Arabia. ( 29942742 )
2018
39
Rabies risk and use of post-exposure prophylaxis associated with dog bites in Tennessee. ( 29430859 )
2018
40
Dog Ecology and Rabies Knowledge of Owners and Non-Owners in Sanur, A Sub-District of the Indonesian Island Province of Bali. ( 29976915 )
2018
41
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6. ( 28491824 )
2017
42
Inhibition of MEK-ERK1/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model. ( 28939254 )
2017
43
A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines. ( 28436708 )
2017
44
Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine? ( 28065475 )
2017
45
Investigating the effect of carbon source on rabies virus glycoprotein production in Pichia pastoris by a transcriptomic approach. ( 28523730 )
2017
46
Level and pattern of human rabies and dog bites in Techiman Municipality in the Middle Belt of Ghana: a six year retrospective records review. ( 29942413 )
2017
47
Rescue of a wild-type rabies virus from cloned cDNA and assessment of the proliferative capacity of recombinant viruses. ( 28447192 )
2017
48
Spatiotemporal epidemic models for rabies among animals. ( 29928742 )
2017
49
Rabies Tracing of Birthdated Dentate Granule Cells in Rat Temporal Lobe Epilepsy. ( 28470680 )
2017
50
Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(Ar)): a global review. ( 28938920 )
2017

Variations for Rabies

Expression for Rabies

Search GEO for disease gene expression data for Rabies.

Pathways for Rabies

Pathways related to Rabies according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CCL5 CD40LG CXCL10 IFNA4 IKBKE IRF3
2
Show member pathways
13.41 CCL5 IFNA4 IKBKE MAP3K8 NFKB1 NGFR
3
Show member pathways
13.34 CCL5 CD40LG CXCL10 IKBKE MAP3K8 NFKB1
4
Show member pathways
13.21 CCL5 CD40LG CXCL10 IKBKE NFKB1 NGFR
5
Show member pathways
13.04 CCL5 CD40LG CXCL10 IFNA4 IRF3 MAP3K8
6
Show member pathways
12.87 CCL5 CXCL10 IFNA4 IKBKE IRF3 MAP3K8
7
Show member pathways
12.85 IFNA4 IKBKE IRF3 MX1 NFKB1 NGFR
8
Show member pathways
12.81 CCL5 CXCL10 NFKB1 STAT1 STAT2
9
Show member pathways
12.81 CCL5 IKBKE MAP3K8 NFKB1 NGFR
10 12.77 IFNA4 NFKB1 PML STAT1 STAT2
11
Show member pathways
12.74 IKBKE IRF3 MAP3K8 NFKB1 NGFR
12
Show member pathways
12.72 CCL5 CXCL10 IFNA4 IKBKE IRF3 NFKB1
13
Show member pathways
12.63 CD40LG IKBKE NFKB1 NGFR TLR3
14
Show member pathways
12.62 CD40LG IKBKE MAP3K8 NFKB1 PML STAT1
15
Show member pathways
12.56 IFNA4 IRF3 MX1 STAT1 STAT2
16
Show member pathways
12.52 IFNA4 IKBKE IRF3 NFKB1 STAT1 STAT2
17
Show member pathways
12.47 CD40LG IKBKE NFKB1 NGFR TLR3
18
Show member pathways
12.44 IFNA4 IRF3 MX1 NCAM1 PML STAT1
19
Show member pathways
12.38 IKBKE NFKB1 STAT1 STAT2
20
Show member pathways
12.34 IKBKE IRF3 NFKB1 TLR3
21
Show member pathways
12.24 IFNA4 NFKB1 STAT1 STAT2
22
Show member pathways
12.22 IKBKE IRF3 NFKB1 STAT1 TLR3
23
Show member pathways
12.2 IKBKE IRF3 NFKB1 TLR3
24 12.17 CCL5 CD40LG CXCL10 IKBKE IRF3 NCAM1
25
Show member pathways
12.15 IKBKE NFKB1 STAT1 STAT2
26
Show member pathways
12.14 IFNA4 STAT1 STAT2 TLR3
27 12.05 NCAM1 NFKB1 NGFR STAT1
28
Show member pathways
12.05 CCL5 CXCL10 IFNA4 IKBKE IRF3 MX1
29
Show member pathways
11.99 CCL5 NGFR STAT1 STAT2
30 11.98 ALB NCAM1 NGFR
31 11.96 NFKB1 STAT1 STAT2
32
Show member pathways
11.94 NFKB1 STAT1 TLR3
33 11.92 IFNA4 IKBKE IRF3 NFKB1 STAT1 STAT2
34 11.89 CCL5 CXCL10 MAP3K8 NFKB1
35 11.84 IFNA4 IKBKE STAT1 STAT2
36
Show member pathways
11.69 CD40LG NFKB1 NGFR
37 11.68 IKBKE MAP3K8 NFKB1
38 11.33 CXCL10 STAT1 STAT2
39
Show member pathways
11.14 IRF3 MX1 STAT1 STAT2

GO Terms for Rabies

Cellular components related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 ALB CCL5 CD40LG CXCL10 IFNA4 NCAM1

Biological processes related to Rabies according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.99 IRF3 MAP3K8 MX1 PML TLR3
2 immune response GO:0006955 9.96 CCL5 CD40LG CXCL10 IKBKE NGFR
3 viral process GO:0016032 9.93 IRF3 NCAM1 PML STAT1 STAT2
4 cytokine-mediated signaling pathway GO:0019221 9.88 CCL5 CXCL10 IFNA4 STAT1 STAT2
5 inflammatory response GO:0006954 9.88 CCL5 CD40LG CXCL10 NFKB1 NGFR TLR3
6 innate immune response GO:0045087 9.87 IFNA4 IKBKE IRF3 MX1 NFKB1 PML
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 CD40LG NFKB1 TLR3
8 cellular response to lipopolysaccharide GO:0071222 9.83 CXCL10 IRF3 NFKB1
9 tumor necrosis factor-mediated signaling pathway GO:0033209 9.83 CD40LG NGFR STAT1
10 negative regulation of angiogenesis GO:0016525 9.81 CXCL10 PML STAT1
11 defense response GO:0006952 9.81 CXCL10 IFNA4 MX1 TLR3
12 cellular response to interferon-gamma GO:0071346 9.79 CCL5 STAT1 TLR3
13 response to cytokine GO:0034097 9.72 CCL5 PML STAT1
14 positive regulation of type I interferon production GO:0032481 9.7 IRF3 NFKB1 TLR3
15 response to exogenous dsRNA GO:0043330 9.67 IFNA4 IRF3 TLR3
16 interferon-gamma-mediated signaling pathway GO:0060333 9.67 IRF3 NCAM1 PML STAT1
17 membrane protein intracellular domain proteolysis GO:0031293 9.65 NFKB1 NGFR
18 positive regulation of monocyte chemotaxis GO:0090026 9.65 CCL5 CXCL10
19 positive regulation of T cell migration GO:2000406 9.63 CCL5 CXCL10
20 cellular response to interferon-beta GO:0035458 9.63 STAT1 TLR3
21 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.63 IKBKE IRF3 TLR3
22 positive regulation of interferon-alpha production GO:0032727 9.62 IRF3 STAT1
23 I-kappaB phosphorylation GO:0007252 9.61 IKBKE TLR3
24 regulation of type I interferon-mediated signaling pathway GO:0060338 9.61 IFNA4 STAT1 STAT2
25 positive regulation of lipid storage GO:0010884 9.6 IKBKE NFKB1
26 response to interferon-beta GO:0035456 9.58 IKBKE STAT1
27 response to type I interferon GO:0034340 9.57 IKBKE MX1
28 response to virus GO:0009615 9.55 CCL5 CXCL10 IFNA4 MX1 TLR3
29 cellular response to dsRNA GO:0071359 9.43 IRF3 NFKB1 TLR3
30 type I interferon signaling pathway GO:0060337 9.35 IFNA4 IRF3 MX1 STAT1 STAT2
31 defense response to virus GO:0051607 9.23 CXCL10 IFNA4 IRF3 MX1 PML STAT1
32 signal transduction GO:0007165 10.19 CXCL10 MAP3K8 MX1 NFKB1 NGFR STAT1
33 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 CXCL10 IRF3 NFKB1 PML STAT1 TLR3
34 apoptotic process GO:0006915 10.04 IRF3 MX1 NFKB1 NGFR PML

Molecular functions related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.86 ALB CCL5 CD40LG CXCL10 IFNA4 IKBKE
2 cytokine activity GO:0005125 9.46 CCL5 CD40LG CXCL10 IFNA4
3 ubiquitin-like protein ligase binding GO:0044389 9.32 STAT1 STAT2
4 CCR5 chemokine receptor binding GO:0031730 9.26 CCL5 STAT1
5 identical protein binding GO:0042802 9.23 ALB CCL5 IRF3 MX1 NFKB1 STAT1

Sources for Rabies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....